S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
NASDAQ:PIRS

Pieris Pharmaceuticals Stock Forecast, Price & News

$5.62
+0.18 (+3.31 %)
(As of 09/24/2021 04:00 PM ET)
Add
Compare
Today's Range
$5.45
$6.15
50-Day Range
$3.35
$5.85
52-Week Range
$1.70
$6.15
Volume3.33 million shs
Average Volume4.41 million shs
Market Capitalization$374.92 million
P/E RatioN/A
Dividend YieldN/A
Beta1.19
30 days | 90 days | 365 days | Advanced Chart
Receive PIRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Pieris Pharmaceuticals logo

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.77 out of 5 stars

Medical Sector

808th out of 1,351 stocks

Pharmaceutical Preparations Industry

401st out of 664 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions

Is Pieris Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Pieris Pharmaceuticals stock.
View analyst ratings for Pieris Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Pieris Pharmaceuticals?

Wall Street analysts have given Pieris Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pieris Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Pieris Pharmaceuticals?

Pieris Pharmaceuticals saw a drop in short interest in the month of August. As of August 13th, there was short interest totaling 1,100,000 shares, a drop of 47.6% from the July 29th total of 2,100,000 shares. Based on an average daily volume of 11,010,000 shares, the short-interest ratio is currently 0.1 days. Approximately 2.0% of the shares of the stock are short sold.
View Pieris Pharmaceuticals' Short Interest
.

When is Pieris Pharmaceuticals' next earnings date?

Pieris Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Pieris Pharmaceuticals
.

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) issued its earnings results on Wednesday, August, 4th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by $0.05. The biotechnology company earned $3.29 million during the quarter, compared to the consensus estimate of $8.53 million. Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 122.26% and a negative net margin of 205.63%.
View Pieris Pharmaceuticals' earnings history
.

How has Pieris Pharmaceuticals' stock been impacted by COVID-19?

Pieris Pharmaceuticals' stock was trading at $2.23 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PIRS shares have increased by 152.0% and is now trading at $5.62.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PIRS?

3 analysts have issued twelve-month price objectives for Pieris Pharmaceuticals' shares. Their forecasts range from $8.00 to $9.00. On average, they anticipate Pieris Pharmaceuticals' stock price to reach $8.50 in the next year. This suggests a possible upside of 51.2% from the stock's current price.
View analysts' price targets for Pieris Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Pieris Pharmaceuticals' key executives?

Pieris Pharmaceuticals' management team includes the following people:
  • Stephen S. Yoder, President, Chief Executive Officer & Director
  • Thomas Bures, Treasurer & Vice President-Finance
  • Hitto Kaufmann, Chief Scientific Officer & Senior Vice President
  • Tim Demuth, Chief Medical Officer & Senior Vice President
  • Shane Olwill, Chief Development Officer & Senior Vice President

What other stocks do shareholders of Pieris Pharmaceuticals own?

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BVF Inc. IL (7.99%), Millennium Management LLC (4.43%), Morgan Stanley (2.51%), Morgan Stanley (2.51%), BlackRock Inc. (1.95%) and Vanguard Group Inc. (1.61%). Company insiders that own Pieris Pharmaceuticals stock include Aquilo Capital Management, Llc and Shane Olwill.
View institutional ownership trends for Pieris Pharmaceuticals
.

Which institutional investors are selling Pieris Pharmaceuticals stock?

PIRS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Renaissance Technologies LLC, Northern Trust Corp, Geode Capital Management LLC, Goldman Sachs Group Inc., Vanguard Group Inc., and JPMorgan Chase & Co..
View insider buying and selling activity for Pieris Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Pieris Pharmaceuticals stock?

PIRS stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Point72 Asset Management L.P., Morgan Stanley, Morgan Stanley, EAM Investors LLC, Ergoteles LLC, Susquehanna International Group LLP, and Squarepoint Ops LLC.
View insider buying and selling activity for Pieris Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $5.62.

How much money does Pieris Pharmaceuticals make?

Pieris Pharmaceuticals has a market capitalization of $374.92 million and generates $29.32 million in revenue each year. The biotechnology company earns $-37,230,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

How many employees does Pieris Pharmaceuticals have?

Pieris Pharmaceuticals employs 117 workers across the globe.

What is Pieris Pharmaceuticals' official website?

The official website for Pieris Pharmaceuticals is www.pieris.com.

Where are Pieris Pharmaceuticals' headquarters?

Pieris Pharmaceuticals is headquartered at 255 State Street 9th Floor, Boston MA, 02109.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at (857) 246-8998 or via email at [email protected].


This page was last updated on 9/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.